NCT04622345View on ClinicalTrials.gov

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 21, 2020

Primary Completion Date

May 22, 2021

Study Completion Date

June 28, 2021

Conditions
Allergic Conjunctivitis
Interventions
DRUG

VSJ-110

ophthalmic solution

DRUG

Placebo

ophthalmic solution

Trial Locations (1)

01810

Vanda Investigational Site, Andover

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY